相关实验视频

Updated: Jan 16, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

一种强大的生物A抑制剂的结构导向开发验证了生物合成抑制作为结核病治疗策略

Qiang Liu¹, Joshua B Wallach², Yahani P Jayasinghe³

¹Department of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, United States.

bioRxiv : the preprint server for biology

|October 3, 2025

概括

研究人员开发了C48,它是一种强大的细菌酶BioA的抑制剂,对生物生物合成至关重要. 这种化合物对Mycobacterium tuberculosis具有有效性,并为结核病提供了一种新的治疗策略.

科学领域:

药用化学医学化学
微生物学微生物学
生物化学生物化学

背景情况:

生物生物合成对于细菌的生存至关重要.
酶氨基转移酶BioA是抗微生物药物开发的验证目标.
现有的抑制剂往往缺乏强度或适当的药理动力学特性.

研究的目的:

开发一种强效和选择性的细菌BioA.抑制剂.
评估抑制剂对Mycobacterium结核病 (Mtb) 的疗效在体外和体内.
建立针对性生物生物合成作为结核病的治疗策略.

主要方法:

结构引导的药物设计和选成功的优化.
生物化学测试以确定酶抑制 (Ki).
针对Mtb和非结核性菌根菌的抗菌素敏感性测试 (MIC).
关于细胞外应力和膜重塑的体外研究.
在低生物素小鼠模型中进行的药理动力学分析和体内疗效研究.

主要成果:

开发了C48,一种强大的BioA抑制剂,其Ki值为200 pM.
在C48中,针对Mtb和非结核性菌根菌的MIC显示为亚微粒度.
实验室研究表明,C48通过诱导细胞外应激来模仿生物素饥饿.
药理动力学研究显示,口服生物利用性很好,药物暴露显著改善.
在一个相关的小鼠模型中,C48有效地减少了肺和脏中的Mtb负担.

结论:

C48是一种高度强效和选择性的BioA抑制剂,具有有前途的抗菌细菌活性.
准细菌生物生物合成是一种可行的结核病治疗策略.
C48代表了一种潜在的新型抗生素类别,用于对抗Mtb.

更多相关视频

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...